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Abstract 
GranuLab Sdn. Bhd. (GranuLab) was formed in 2005 to host the development and 
commercialization of a patented synthetic bone graft substitute, made from limestone and 
pure chemicals, called GranuMaS. The GranuMaS technology was invented by a group of 
researchers, led by one from SIRIM. The research began in 2000, and in 2005, GranuLab 
founders identified a huge business opportunity for GranuMaS. They then developed the 
business opportunity, resulting in the transfer of GranuMaS technology to GranuLab, and in 
turn GranuLab being acquired by Sindora in mid-2007. By then, the founders had to think of 
its next course of action. But, they realized the need to first educate GranuLab’s parent 
company on managing a technology-based venture, particularly one that involved an invasive 
medical technology. This case describes the process of innovation of the medical technology, 
technology transfer, and entrepreneurship at GranuLab, leading to the commercialization of 
GranuMaS. It is designed to stimulate critical thinking of the process of innovation and 
entrepreneurship, and provide understanding of the process of a medical technology 
commercialization. 
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